| | |

Tracking Mesothelioma Recurrence: FDG-PET/CT Versus CT

tracking mesothelioma recurrence

FDG-PET/CT may be a more effective way to track malignant pleural mesothelioma recurrence than contrast-enhanced CT scanning. 

That is the conclusion of cancer researchers with Japan’s Hyogo College of Medicine.

The researchers focused on fifty patients who underwent radical surgery for pleural mesothelioma. Afterwards, doctors used both FDG-PET/CT and contrast-enhanced CT scans to track mesothelioma progression.

Two experienced examiners assessed the cases. They concluded that FDG-PET/CT was more accurate than CT for diagnosing mesothelioma recurrence.

Mesothelioma Recurrence After Surgery

Pleural mesothelioma is one of the most difficult cancers to treat. It arises in the layers of the pleural membrane that surrounds the lungs. Mesothelioma tumors tend to grow and spread quickly.

Treatments like chemotherapy, surgery, and radiotherapy can sometimes slow down mesothelioma progression. But mesothelioma recurrence is common, even with the best therapies. 

To treat a recurrent tumor, doctors first have to know about it. Patients do not always have symptoms right away when a mesothelioma tumor starts to grow again. 

If mesothelioma recurrence is suspected, doctors may use imaging technologies like PET scans or CT scans to confirm it.

FDG-PET/CT Versus CT Scanning

Positron Emission Tomography (PET) scanning tracks the metabolic rate of cells. Fast metabolizing cells like mesothelioma cells show up as bright spots on PET scans. Injecting a tracer called fluorodeoxyglucose (FDG) before the PET scan enhances the effect. 

Computed tomography (CT) scans take a series of X-ray images from different angles. The images are combined to create a 3D picture of a mesothelioma tumor. Both types of imaging studies can show mesothelioma recurrence. 

In the new Japanese study, 50 patients suspected of mesothelioma recurrence had both kinds of tests. Researchers compared the tests with each other and with pathology results. Patients were tracked for six months or more to confirm whether or not their tumors really had grown. 

Diagnosing Mesothelioma Progression

Mesothelioma progressed in 40 of the patients. Fourteen patients had a change in their treatment plan based on their FDG-PET/CT results. 

Additionally, FDG-PET/CT showed six cases of mesothelioma recurrence that did not show up on CT scans. In four cases, this led to a change of treatment. 

Lead author Kazuhiro Kitajima concludes, “FDG-PET/CT findings were shown to be more accurate for assessing malignant pleural mesothelioma recurrence and more often led to therapy change than contrast-enhanced CT.”

Accurate assessment of mesothelioma recurrence is critical to survival. Most pleural mesothelioma patients have a life expectancy of fewer than 18 months. 

Source:

Kitajima, K, et al, “Clinical utility of FDG-PET/CT for post-surgery surveillance of malignant pleural mesothelioma – Comparison with contrast-enhanced CT”, November 26, 2019, Oncotraget, pp. 6816-6828, http://www.oncotarget.com/index.php?journal=oncotarget&page=article&op=view&path[]=27324&path[]=88726

Similar Posts

  • |

    Mesothelioma Still Rising Despite Ban in Ireland

    A study in Ireland confirms that it can take many years for a ban on asbestos to have a measurable impact on a country’s rates of malignant mesothelioma. Mesothelioma is the most serious of a list of diseases – including lung cancer, pleural plaques, asbestosis, and others – linked with exposure to asbestos dust. Affecting the linings around the lungs and other organs, mesothelioma is often resistant to most cancer treatments and may be fatal within a year of diagnosis. According to the International Ban Asbestos Secretariat, Ireland is one of 55 countries that have enacted some type of asbestos ban. However, although Ireland banned asbestos in 2000, a new study published in Cancer Epidemiology shows that incidence of the…

  • |

    Website Aims to Protect Homeowners from Mesothelioma

    Australia’s Cancer Council is trying to educate home renovators about their risk for mesothelioma with a new e-learning course. Australia has one of the highest per capita rates of mesothelioma in the world, largely because of several asbestos mining operations that were once located there. Although asbestos has been banned from building products in Australia since 1989, asbestos-linked diseases like mesothelioma, lung cancer, and asbestosis continue to pose a serious health concern. While mesothelioma has traditionally occurred among people exposed to asbestos on the job, Australia is now bracing for another “wave” of mesothelioma victims among homeowners who encounter asbestos while doing their own renovation projects. Cancer Council Australia has launched “kNOw asbestos in your home” in an effort to…

  • | | |

    Mesothelioma Nurses Ready for New Cases in Australia

    Australia is bracing for an expected new wave of mesothelioma cases in the next decade and the Lung Foundation of Australia is taking action now to get ready. The Foundation has paid for ten nurses from around the country to receive specialized training in helping patients and families cope with mesothelioma. The nurses, who have recently completed the training, are now equipped to lead treatment planning for these complex cancer patients and to help other nurses do the same. Pleural mesothelioma is an aggressive cancer that occurs in the lining around the lungs. It is caused by exposure to asbestos dust, a toxin that was once alarmingly prevalent in Australia where it was mined and heavily used in construction. Because…

  • |

    Mesothelioma Blood Test May Be Possible

    An international team of researchers is studying the proteins found on the surface of cancer cells in an effort to improve mesothelioma diagnosis. The team, made up of scientists from the US, Switzerland, Italy and Chile, has just published their findings on a new kind of test to identify protein-derived mesothelioma biomarkers in blood serum. Mesothelioma is an aggressive cancer of the membranes around organs. Because the most common mesothelioma biomarker, mesothelin, is also overproduced by other kinds of cancer cells, it has only limited diagnostic value. A test to identify a set of proteins produced specifically by mesothelioma cells could greatly improve diagnostic accuracy. Led by Ferdinando Cerciello and Bernd Wollscheid of the Institute of Molecular Systems Biology in…

  • | |

    Spanish Mesothelioma Deaths Likely to Continue for Decades

    New research in Spain suggests that mesothelioma deaths will continue in the country until the “last surviving member” of the group of people exposed to occupational asbestos succumbs to the disease. Like many countries, Spain used asbestos heavily in the first half of the 20th century, especially in construction, where the mineral was prized for its durability, low cost, and resistance to fire and corrosion.  Asbestos was banned in Spain in 2002. Observing that more than 2.5 million metric tons of asbestos were imported into Spain from 1906 to 2002, researchers say deaths from mesothelioma have risen steadily. Between 1976 and 1980, a total of 491 Spanish people died of mesothelioma. By the 5-year period from 2006 to 2010, that…

  • | |

    Needle Biopsy “Simple, Safe & Accurate” for Mesothelioma

    Mesothelioma researchers in China say a biopsy method that involves a single skin puncture can produce good diagnostic results for mesothelioma patients with little pain or risk. The study focused on percutaneous (through the skin) biopsy in patients who had unexplained fluid buildup or swelling in their abdomens. Abdominal distension and fluid buildup (called ascites) can be signs of peritoneal mesothelioma, a rare but aggressive cancer of the abdominal lining caused by exposure to asbestos. Peritoneal mesothelioma accounts for less than 30% of all mesothelioma cases. Because the symptoms may be vague and often develop many decades after asbestos exposure, peritoneal mesothelioma can be especially challenging to diagnose.  Misdiagnosis and under-diagnosis are not uncommon. In the newest study on percutaneous…